anti-Cytochrome P450, Family 2, Subfamily B, Polypeptide 6 (CYP2B6) Antibodies

CYP2B6, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2B6 Kits (8) and CYP2B6 Proteins (4) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
CYP2B6 1555 P20813
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online

Top anti-CYP2B6 Antibodies at

Showing 10 out of 90 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Cow Rabbit Un-conjugated WB WB Suggested Anti-CYP2B6 Antibody Titration:  0.2-1 ug/ml  ELISA Titer:  1:312500  Positive Control:  THP-1 cell lysate Host:  Mouse  Target Name:  CYP2B10  Sample Tissue:  Mouse Pancreas  Antibody Dilution:  1ug/ml 100 μL 2 to 3 Days
Human Rabbit Un-conjugated ELISA, WB Western blot analysis of extracts from HT-29 cells, using Cytochrome P450 2B6 Antibody. The lane on the right is treated with the synthesized peptide. 100 μg 2 to 3 Days
Human Rabbit Un-conjugated IC, IF, IHC, WB Immunofluorescent analysis of Cytochrome P450 2B6 staining in HepG2 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark. DAPI was used to stain the cell nuclei (blue). Immunohistochemical analysis of Cytochrome P450 2B6 staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. 200 μL 13 to 14 Days
Human Mouse Un-conjugated FACS, IF, IHC, WB Anti-CYP2B6 mouse monoclonal antibody (ABIN2455580) immunofluorescent staining of COS7 cells transiently transfected by pCMV6-ENTRY CYP2B6 (RC217236). HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CYP2B6 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 µg per lane) were separated by SDS-PAGE and immunoblotted with anti-CYP2B6. 0.1 mL 2 to 3 Days
Human Goat Un-conjugated ELISA, WB   100 μg 6 to 7 Days
Human Rabbit Un-conjugated IHC, WB Western blot analysis of extracts of various cell lines, using CYP2B6 antibody (ABIN5997556) at 1/1000 dilution. Immunohistochemistry of paraffin-embedded human lung using CYP2B6 antibody (ABIN5997556) at dilution of 1/100 (40x lens). 100 μL 11 to 18 Days
Human Rabbit Un-conjugated IHC, IHC (p), WB 100 μL 11 to 14 Days
Human Rabbit Un-conjugated ELISA, IF, IHC, WB 100 μL Available
Human Rabbit Un-conjugated ELISA, WB 100 μL Available
Human Rabbit Un-conjugated ELISA, IHC, IHC (p), WB Human Brain, Cortex: Formalin-Fixed, Paraffin-Embedded (FFPE) 50 μL 11 to 14 Days

Top referenced anti-CYP2B6 Antibodies

  1. Human Monoclonal CYP2B6 Primary Antibody for FACS, IF - ABIN2718982 : Sim, Nam, Lee, Lee, O, Joo, Liu, Han, Ki, Jeong, Lee, Lee: Selective induction of hepatic cytochrome P450 2B activity by leelamine in vivo, as a potent novel inducer. in Archives of pharmacal research 2015 (PubMed)
    Show all 3 Pubmed References

  2. Dog (Canine) Monoclonal CYP2B6 Primary Antibody for FACS, ICC - ABIN4302090 : Kim, Choi, Li, Arizpe, Wooton-Kee, Anakk, Jung, Finegold, Moore: Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis. in Endocrinology 2019 (PubMed)

More Antibodies against CYP2B6 Interaction Partners

Human Cytochrome P450, Family 2, Subfamily B, Polypeptide 6 (CYP2B6) interaction partners

  1. CYP2B6 metabolizer strata do not have a statistically significant association with either depression or 6-month viral suppression. In analyses restricted to participants without pre-ART depression, poorer CYP2B6 metabolism is associated with increased odds of depression. Efavirenz-metabolizing allele patterns are strongly associated with risk of incident depression in Ugandan persons living with HIV.

  2. CONCLUSIONS: This study demonstrated that BMI influences propofol pharmacokinetics after its administration as a single intravenous injection, while UGT1A9 and CYP2B6 SNPs, other clinical factors, and hemodynamic variables do not.

  3. Study concludes that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6 variants differ in nicotine metabolism activity but did not find evidence of CYP2B6 activity in human brain.

  4. No significant association was detected between CYP2B6 516G>T polymorphism and susceptibility to ARV-associated hepatotoxicity.

  5. Case Reports: CYP2B6-deficient alleles may be responsible for an increased conversion of ifosfamide into neurotoxic metabolites, leading to encephalopathy.

  6. The concentration-time curve (AUC(0(R)96)), maximum plasma concentration (Cmax), and terminal half-life (t1/2) values of Bupropion in CYP2B6*1/*4 were lower than those of CYP2B6*1/*1. The hydroxybupropion (HBUP) Cmax values in CYP2B6*4/*6 and CYP2B6*1/*4 increased by 1.12-fold and 1.97-fold, whereas the HBUP Cmax value in CYP2B6*1/*6 decreased to a value 1.64-fold lower than that in CYP2B6*1/*1

  7. CYP2B6-efavirenz analog complex provides a useful platform to investigate computationally as well as biophysically the effect of genetic polymorphisms on binding of the widely studied efavirenz.

  8. results indicate that the amino acid substitutions in the CYP2B6 variants suppressed the metabolic activation of CPS. CYP2B6 variants have altered capacity to bioactivate CPF and may affect individual susceptibility of CPF

  9. The findings of this study indicate that CYP2B6 contribute to the metabolism of MDMA to MDA in humans

  10. The first data of several CYP2B6 polymorphisms in Roma population.

  11. With consensus recommendations on downregulation, CYP2C induction, and CYP2B6 positive control.

  12. Genotyping of CYP2B6 may therefore be of value when assessing dose requirements in methadone maintenance treatment.

  13. Genomic variation in CYP2B6 may explain, at least in part, severity of Neonatal Abstinence Syndrome

  14. CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-Infected children.

  15. This is the first study that investigated the impact of the 516 G>T polymorphism of the CYP2B6 gene among HIV-positive individuals from southern Brazil. Its clinical significance indicates the need for prospective studies in this population.

  16. G(516)T CYP2B6 polymorphisms was associated with Bronchopulmonary Dysplasia susceptibility in Preterm Neonates.

  17. The deficient CYP2B6 516 T allele is associated with higher efavirenz plasma drug levels and more frequent central nervous system-related symptoms.

  18. Males with the CYP2B6 *6/*6 genotype may be less susceptible to the development of anti-tuberculosis drug-induced hepatotoxicity.

  19. CYP2B6 interindividual variability was not significantly associated with genetic variation in CYP2B6, nor was it associated with differences in gender or ethnicity, suggesting that factors other than these are largely responsible for the wide range of variability in CYP2B6 expression and activity observed among a large group of individuals/samples.

  20. Established the regression models for CYP3A4 and CYP2B6 inductions in human hepatocytes using azole compounds.

CYP2B6 Antigen Profile

Protein Summary

This gene, CYP2B6, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide. Transcript variants for this gene have been described\; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely related pseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.

Gene names and symbols associated with CYP2B6

  • cytochrome P450 family 2 subfamily B member 6 (CYP2B6) antibody
  • cytochrome P450, family 2, subfamily B, polypeptide 6 (CYP2B6) antibody
  • cytochrome P450 family 2 subfamily B member 6 L homeolog (cyp2b6.L) antibody
  • cytochrome P450 2B11 (CYP2B6) antibody
  • cytochrome P450 subfamily 2B (CYP2B6) antibody
  • cytochrome P450 2B11-like (LOC100068603) antibody
  • CPB6 antibody
  • CYP2B antibody
  • CYP2B6 antibody
  • CYP2B7 antibody
  • CYP2B7P antibody
  • CYP2B11 antibody
  • CYP2B30 antibody
  • CYPIIB6 antibody
  • CYPIIB11 antibody
  • EFVM antibody
  • IIB1 antibody
  • P450 antibody

Protein level used designations for CYP2B6

1,4-cineole 2-exo-monooxygenase , cytochrome P450 2B6 , cytochrome P450 IIB1 , cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6 , cytochrome P450 CYP2B30 , cytochrome P450, family 2, subfamily B, polypeptide 6 , cytochrome P450 PBD-2 , cytochrome P450, family 2, subfamily B, polypeptide 11 , cytochrome P450 subfamily 2B , Cytochrome P450 2B6 , LOW QUALITY PROTEIN: cytochrome P450 2B11-like , cytochrome P450 2B11-like

1555 Homo sapiens
678687 Macaca mulatta
494798 Xenopus laevis
474177 Canis lupus familiaris
504769 Bos taurus
100068603 Equus caballus
Selected quality suppliers for anti-CYP2B6 (CYP2B6) Antibodies
Did you look for something else?